Search academic texts

Information × Registration Number 0223U001213, 0120U102954 , R & D reports Title Investigate the effect of different pharmacotherapeutic treatment programs on the structural and functional state of the heart in patients with myocarditis popup.stage_title Head Kovalenko Volodymyr M., Доктор медичних наук Registration Date 25-01-2023 Organization State Institution "National Scientific Center "Institute of Cardiology, clinical and regenerative medicine named after academician M.D. Strazhesko" of the National Academy of Medical Sciences of Ukraine popup.description2 Key words: myocarditis, structural and functional state of the heart, treatment, predictors, heart failure. The object of the study: patients with myocarditis. Purpose: To conduct an analysis of various treatment programs for myocarditis with reduced LV EF in patients with and without a history of COVID-19 based on a comprehensive study of dynamic changes in the structural and functional state of the heart. Methods and equipment: study of echocardiographic parameters on the Aplio Artida SSH - 880 CV ultrasound machine, magnetic resonance imaging of the heart on the Toshiba Vantage Titan HSR 1.5 Tesla machine, heart rhythm and conduction disorders, HRV indicators on the Philips Digitrak TM-plus HM ECG machine 3100A. It was found that patients with a history of COVID-19 infection who took the sacubitril-valsartan combination for 6 months had a higher exercise tolerance by an average of 9.6 % (p<0.05) according to the 6-minute test, significantly larger values of LV EF (by 9.8 % on average), LV GLS and LV CLS (on average by 11.8 % and 10.2 %, respectively), as well as significantly fewer LV segments affected by fibrotic changes, on average by 22.5 %), and 1.5 and 2 times fewer ventricular extrasystoles and episodes of unstable ventricular tachycardia, respectively, compared to patients who received therapy with ACE inhibitors. In post-COVID-19 myocarditis patients with LV EF ≤ 40 % during 6 months of ACE inhibitor therapy, switching to sacubitril-valsartan resulted in an 18.2 % increase in LV EF and a 12.5 % increase in LV GLS at 12 months. To predict the effectiveness of the sacubitril-valsartan combination in patients with myocarditis in terms of improving the structural and functional state of the heart after 12 months, a multivariate regression model was created to establish predictors of normalization of LV EF and EDV. Product Description popup.authors Halytska Anastasia Kostyantynivna Kirichenko Roman Mykhailovych Kornienko Tetiana M. Lichman Olexandr M. Marchenko Kateryna Serhiivna Nesukai Olena H. Ryabenko Dmytro Vasylovich Slyvna Anastasia Borysivna Titov Evgenii Yu. Titova Natalia S. Cherniuk Sergii Volodymyrovich popup.nrat_date 2023-01-25 Close